Frontiers in Endocrinology (Oct 2023)
Editorial: Decoding checkpoint inhibitor-induced immune-related adverse events, volume II
- Deborah L. Burnett,
- Deborah L. Burnett,
- Megan B. Barnet,
- Megan B. Barnet,
- Megan B. Barnet,
- Ania Moxon,
- Venessa Tsang,
- Venessa Tsang,
- Katherine Samaras,
- Katherine Samaras,
- Katherine Samaras
Affiliations
- Deborah L. Burnett
- Immunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- Deborah L. Burnett
- School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales (UNSW), Sydney, NSW, Australia
- Megan B. Barnet
- Immunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- Megan B. Barnet
- School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales (UNSW), Sydney, NSW, Australia
- Megan B. Barnet
- Department of Medical Oncology, St Vincent’s Hospital, Darlinghurst, NSW, Australia
- Ania Moxon
- Immunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- Venessa Tsang
- Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
- Venessa Tsang
- Department of Endocrinology, Royal North Shore Hospital, St Leonards, NSW, Australia
- Katherine Samaras
- School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales (UNSW), Sydney, NSW, Australia
- Katherine Samaras
- Department of Endocrinology, St Vincent’s Hospital, Darlinghurst, NSW, Australia
- Katherine Samaras
- Clinical Obesity, Nutrition, and Adipose Biology Lab, Clinical Science Pillar, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- DOI
- https://doi.org/10.3389/fendo.2023.1317220
- Journal volume & issue
-
Vol. 14
Abstract
No abstracts available.Keywords
- immune related adverse effects
- immune check inhibitor (ICI)
- PD-1 - PD-L1 axis
- CTLA -4
- cancer immunotherapy
